Stevens-Johnson Syndrome

"Stevens-Johnson Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Rare cutaneous eruption characterized by extensive KERATINOCYTE apoptosis resulting in skin detachment with mucosal involvement. It is often provoked by the use of drugs (e.g., antibiotics and anticonvulsants) or associated with PNEUMONIA, MYCOPLASMA. It is considered a continuum of Toxic Epidermal Necrolysis.

Descriptor ID	D013262
MeSH Number(s)	C07.465.864.500 C17.800.174.600.900 C17.800.229.400.683 C17.800.865.475.683 C20.543.206.380.900 C25.100.468.380.900
Concept/Terms	Stevens-Johnson Syndrome Stevens-Johnson Syndrome Stevens Johnson Syndrome Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum Stevens Johnson Syndrome Toxic Epidermal Necrolysis Spectrum Toxic Epidermal Necrolysis Stevens-Johnson Syndrome Spectrum Toxic Epidermal Necrolysis Stevens Johnson Syndrome Toxic Epidermal Necrolysis Stevens Johnson Syndrome Spectrum Toxic Epidermal Necrolysis Stevens-Johnson Syndrome Stevens Johnson Syndrome Toxic Epidermal Necrolysis Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Mycoplasma-Induced Stevens-Johnson Syndrome Mycoplasma-Induced Stevens-Johnson Syndrome Mycoplasma Induced Stevens Johnson Syndrome Stevens-Johnson Syndrome, Mycoplasma-Induced Syndrome, Mycoplasma-Induced Stevens-Johnson Mycoplasma-Induced Stevens Johnson Syndrome Drug-Induced Stevens Johnson Syndrome Drug-Induced Stevens Johnson Syndrome Drug Induced Stevens Johnson Syndrome Drug-Induced Stevens-Johnson Syndrome Drug-Induced Stevens-Johnson Syndromes Stevens-Johnson Syndrome, Drug-Induced Stevens-Johnson Syndromes, Drug-Induced Epidermal Necrolysis, Toxic Epidermal Necrolysis, Toxic Epidermal Necrolyses, Toxic Necrolyses, Toxic Epidermal Necrolysis, Toxic Epidermal Toxic Epidermal Necrolyses Toxic Epidermal Necrolysis Scalded Skin Syndrome, Nonstaphylococcal Lyell's Syndrome Lyell Syndrome Lyell's Syndromes Syndrome, Lyell's Syndromes, Lyell's Nonstaphylococcal Scalded Skin Syndrome

Below are MeSH descriptors whose meaning is more general than "Stevens-Johnson Syndrome".

Diseases [C]
Stomatognathic Diseases [C07]
Mouth Diseases [C07.465]
Stomatitis [C07.465.864]
Stevens-Johnson Syndrome [C07.465.864.500]
Skin and Connective Tissue Diseases [C17]
Skin Diseases [C17.800]
Dermatitis [C17.800.174]
Drug Eruptions [C17.800.174.600]
Stevens-Johnson Syndrome [C17.800.174.600.900]
Erythema [C17.800.229]
Erythema Multiforme [C17.800.229.400]
Stevens-Johnson Syndrome [C17.800.229.400.683]
Skin Diseases, Vesiculobullous [C17.800.865]
Erythema Multiforme [C17.800.865.475]
Stevens-Johnson Syndrome [C17.800.865.475.683]
Immune System Diseases [C20]
Hypersensitivity [C20.543]
Drug Hypersensitivity [C20.543.206]
Drug Eruptions [C20.543.206.380]
Stevens-Johnson Syndrome [C20.543.206.380.900]
Chemically-Induced Disorders [C25]
Drug-Related Side Effects and Adverse Reactions [C25.100]
Drug Hypersensitivity [C25.100.468]
Drug Eruptions [C25.100.468.380]
Stevens-Johnson Syndrome [C25.100.468.380.900]

Below are MeSH descriptors whose meaning is related to "Stevens-Johnson Syndrome".

Below are MeSH descriptors whose meaning is more specific than "Stevens-Johnson Syndrome".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Stevens-Johnson Syndrome" by people in this website by year, and whether "Stevens-Johnson Syndrome" was a major or minor topic of these publications.

Bar chart showing 7 publications over 7 distinct years, with a maximum of 1 publications in 2006 and 2017 and 2019 and 2021 and 2022 and 2023 and 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2006	1	0	1
2017	1	0	1
2019	0	1	1
2021	1	0	1
2022	1	0	1
2023	1	0	1
2024	0	1	1

Below are the most recent publications written about "Stevens-Johnson Syndrome" by people in Profiles.

Shah PN, Romar GA, Manukyan A, Ko WC, Hsieh PC, Velasquez GA, Schunkert EM, Fu X, Guleria I, Bronson RT, Wei K, Waldman AH, Vleugels FR, Liang MG, Giobbie-Hurder A, Mostaghimi A, Schmidt BA, Barrera V, Foreman RK, Garber M, Divito SJ. Systemic and skin-limited delayed-type drug hypersensitivity reactions associate with distinct resident and recruited T cell subsets. J Clin Invest. 2024 Jul 23; 134(17).

View in: PubMed
Waters M, Dobry A, Le ST, Shinkai K, Beachkofsky TM, Davis MDP, Dominguez AR, Kroshinsky D, Markova A, Micheletti RG, Mostaghimi A, Pasieka HB, Rosenbach M, Seminario-Vidal L, Trinidad J, Albrecht J, Altman EM, Arakaki R, Ardern-Jones M, Bridges AG, Cardones AR, Chadha AA, Chen JK, Chen ST, Cheng K, Daveluy S, DeNiro KL, Harp J, Keller JJ, King B, Korman AM, Lowenstein EJ, Luxenberg E, Mancuso JB, Mauskar MM, Milam P, Motaparthi K, Nelson CA, Nguyen CV, Nutan F, Ortega-Loayza AG, Patel T, Rahnama-Moghadam S, Rekhtman S, Rojek NW, Sarihan M, Shaigany S, Sharma TR, Shearer SM, Shields BE, Strowd LC, Tartar DM, Thomas C, Wanat KA, Walls AC, Zaba LC, Ziemer CM, Maverakis E, Kaffenberger BH. Development of a Skin-Directed Scoring System for Stevens-Johnson Syndrome and Epidermal Necrolysis: A Delphi Consensus Exercise. JAMA Dermatol. 2023 07 01; 159(7):772-777.

View in: PubMed
Lee O, Masood M, Nutan F. Case Series of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis With Nivolumab and Nivolumab/ Ipilimumab Combination Therapy in Metastatic Melanoma. J Drugs Dermatol. 2022 May 01; 21(5):529-530.

View in: PubMed
Hoffman M, Chansky PB, Bashyam AR, Boettler MA, Challa N, Dominguez A, Estupinan B, Gupta R, Hennessy K, Huckell SN, Hylwa-Deufel S, Karikari NA, Keller JJ, Kroshinsky D, Kullberg SA, Lake E, Lee KJ, Martinez E, Michels K, Mostaghimi A, Murphy W, Nutan F, Osler M, Pahalyants V, Patel T, Seminario-Vidal L, Strowd LC, Trinidad J, Vaudreuil A, Voller LM, Micheletti RG. Long-term Physical and Psychological Outcomes of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. JAMA Dermatol. 2021 Jun 01; 157(6):712-715.

View in: PubMed
Riano I, Cristancho C, Treadwell T. Stevens-Johnson Syndrome-Like Reaction After Exposure to Pembrolizumab and Recombinant Zoster Vaccine in a Patient With Metastatic Lung Cancer. J Investig Med High Impact Case Rep. 2020 Jan-Dec; 8:2324709620914796.

View in: PubMed
Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019 Sep; 6(9):e459-e469.

View in: PubMed
St John J, Ratushny V, Liu KJ, Bach DQ, Badri O, Gracey LE, Ho AW, Raff AB, Sugai DY, Schalock P, Kroshinsky D. Successful Use of Cyclosporin A for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Three Children. Pediatr Dermatol. 2017 Sep; 34(5):540-546.

View in: PubMed
Rodriguez G, Trent JT, Mirzabeigi M, Zaulyanov L, Bruce J, Vincek V. Toxic epidermal necrolysis in a mother and fetus. J Am Acad Dermatol. 2006 Nov; 55(5 Suppl):S96-8.

View in: PubMed
Layton D, Marshall V, Boshier A, Friedmann P, Shakir SA. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. Drug Saf. 2006; 29(8):687-96.

View in: PubMed

People

Explore

Similar Concepts

Top Journals